Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW
Blood. 2017 Jan 10;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.
Grazia G
Cell Death Dis. 2014 Oct 2;5(10):e1434. doi: 10.1038/cddis.2014.410
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Carlo-Stella C
PLoS One. 2013 Apr 19;8(4):e61603. doi: 10.1371/journal.pone.0061603
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.
Zappasodi R
Blood. 2011 Aug 22;118(16):4421-30. doi: 10.1182/blood-2011-06-364570
Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines.
Anichini A
Blood. 2005 Sep 8;107(2):602-9.
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene.
Khobta A, Carlo-Stella C, Capranico G
Cancer Res. 64(8):2656-62.
Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias.
Bonati A
Cancer Res. 60(3):728-32.
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C
Blood. 88(8):3091-100.
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).
Carlo-Stella C
Blood. 72(4):1293-9.
Significance of marrow-blood barrier for CFU-GM in patients with acute nonlymphoid leukemia (AnLL).
Ghizzi A
Haematologica. 70(4):303-8.